Want to see NVCT full AI Analyst Report?
NVCT Stock Chart & Stats
$19.31
$0.12(0.62%)
At close: 4:00 PM EDT
$19.31
$0.12(0.62%)
Day’s Range― - ―
52-Week Range$5.55 - $29.28
Previous CloseN/A
Volume13.30K
Average Volume (3M)89.48K
Market Cap
$621.66M
Enterprise Value$409.56
Total Cash (Recent Filing)$22.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 10, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding32,581,530
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$34.00Price Target Upside76.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Equity Funding RunwayThe recent ~$93M equity raise meaningfully extends runway and funds clinical development across lead programs. For a pre-revenue biotech, secured capital reduces near-term financing risk, allowing sustained R&D execution and trial advancement without immediate dilution from emergency financings.
Pipeline Expansion (Haisco License)Acquiring two clinical-stage assets diversifies the company's development portfolio into high-value complement and BRAF- mutant oncology markets. This transforms Nuvectis from single-program risk toward multiple value drivers, improving long-term commercial opportunity and strategic positioning in rare disease and oncology.
Debt-free Capital StructureA no-debt balance sheet provides financial flexibility for R&D spending, partnerships and potential M&A without fixed interest burdens. This durable structural advantage lowers bankruptcy risk and improves negotiating power with licensors and CROs while equity cushions absorb development volatility.
Bears Say
Pre-revenue OperationsAs a clinical-stage company with no product revenue, Nuvectis depends entirely on external financing and milestone deals to fund operations. Persistent net losses erode equity and make long-term sustainability contingent on successful trials or continued capital markets access, raising execution risk.
Consistent Negative Cash FlowRepeated negative operating and free cash flow means cash burn is structural, not transitory. Continued negative FCF compels periodic capital raises, which can dilute shareholders and constrain strategic choices if market access tightens, potentially delaying or compressing development timelines.
Deal Obligations And Dilution RiskThe license expands assets but creates material contingent liabilities (upfront fee, milestones, royalties) and financing conditions that may trigger additional funding needs or future dilution. These obligations increase fixed development costs and commercial economics risk if programs underperform.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $29.27 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $621.66M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Nov 10, 2026 which is in 82 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.262 by -$0.038.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.23.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 32,581,530 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.262. Following the earnings report the stock price went down -6.944%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (76.07% Upside)
$34.00 (76.07% Upside)
Blogger Sentiment
Bullish
NVCT Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.76%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
NVCT Stock 12 Month Forecast
Average Price Target
$34.00
▲(76.07% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
34.92% Insiders
3.61% Mutual Funds
18.17% Other Institutional Investors
37.63% Public Companies and
Individual Investors